Jenifer Zhai, MD
Neurology · Springfield, MONPI 1144388745
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,543 of the $42,214 with a category attached, or 77.1%. Sanofi accounts for 92.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $33,662 and has fallen 99.1% since, to $303 in 2024.
Across 70 payments — averaging $603.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$39K
- Argenx US, Inc.$2K
- Medtronic$532
- TG Therapeutics, Inc.$123
- AbbVie$109
- AstraZeneca$98
- plus $413 from 6 others
Across 3 payments — averaging $1957.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$6K
What the payments were for
- Consulting fees$4,61811%
- Speaking & faculty fees$32,54377%
- Travel & lodging$2,5086%
- Food & beverage$2,5466%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 50 | $39,173 |
| Argenx US, Inc. | 3 | $1,765 |
| Medtronic | 4 | $532 |
| TG Therapeutics, Inc. | 1 | $123 |
| AbbVie | 3 | $109 |
| AstraZeneca | 1 | $98 |
| Biogen | 1 | $98 |
| EMD Serono, Inc. | 1 | $97 |
| Amgen | 1 | $97 |
| Lilly USA, LLC | 3 | $84 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,214 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 25 | $657,843 |
| FingolimodFingolimod Hcl | 57 | $245,676 |
| TecfideraDimethyl Fumarate | 25 | $226,368 |
| CopaxoneGlatiramer Acetate | 26 | $164,336 |
| Teriflunomide | 81 | $153,572 |
| AubagioTeriflunomide | 16 | $148,184 |
| Aimovig AutoinjectorErenumab-Aooe | 165 | $134,952 |
| ZeposiaOzanimod Hydrochloride | 11 | $115,265 |
| Glatiramer Acetate | 33 | $88,847 |
| QuliptaAtogepant | 43 | $51,126 |
| BriviactBrivaracetam | 29 | $48,792 |
| Emgality PenGalcanezumab-Gnlm | 54 | $45,336 |
| VimpatLacosamide | 23 | $39,564 |
| Lacosamide | 291 | $33,529 |
| GlatopaGlatiramer Acetate | 12 | $31,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys, Tecfidera | $98 | $884,21050 claims |
| SanofiAubagio | $39,173 | $148,18416 claims |
| AbbVieQulipta, Ubrelvy, Namzaric | $109 | $82,19471 claims |
| PfizerNurtec Odt | $18 | $21,77216 claims |
| Lilly USA, LLCReyvow | $84 | $16,75323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 381 neurology providers in Missouri.
Other neurology in Springfield
- Jennifer LynchSpringfield$33K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Daniel MattsonBridgeton$451K
- Siddharth KaulBridgeton$387K
- Barbara GreenChesterfield$352K
- Steven KosaNorth Kansas City$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.